In patients with NVAF, ELIQUIS is the only factor Xa inhibitor to demonstrate:
ELIQUIS has been compared with warfarin in a Phase III trial for the prevention of stroke / systemic embolism in patients with NVAF.2
Learn more about the ARISTOTLE trial.
ELIQUIS is the only NOAC to be compared with a pre-specified aspirin treatment arm in a Phase III trial in patients with NVAF considered unsuitable for warfarin.3
Learn more about the AVERROES trial.
Favourable efficacy and major bleeding outcomes vs. warfarin, demonstrated in randomised controlled trials,1 are now reflected by real-world experience in the USA.4
Learn more about ELIQUIS real world data.